You are here

Marburg Virus Prophylactic Medical Countermeasure

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-P-0299
Agency Tracking Number: C18A-002-0003
Amount: $149,998.71
Phase: Phase I
Program: STTR
Solicitation Topic Code: CBD18A-002
Solicitation Number: 2018.0
Timeline
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-27
Award End Date (Contract End Date): 2019-03-27
Small Business Information
6160 Lusk Blvd., Suite C105, San Diego, CA, 92121
DUNS: 137551797
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Larry Zeitlin
 (443) 629-0104
 larry.zeitlin@mappbio.com
Business Contact
 Jane Ennis
Phone: (647) 668-2267
Email: jane.ennis@mappbio.com
Research Institution
 University of Texas Medical Branch
 Larry Zeitlin
 301 University Boulevard
Galveston, TX, 77555
 (443) 629-0104
 Nonprofit college or university
Abstract
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the context of operationalreadiness. Perhaps most significant is that vaccines require the host to develop an appropriate immune response. This response must be ofsufficient strength and also of appropriate specificity. Further, development of an immune response can take on the order of 1-6 monthsdepending upon how many boosts are required. Monoclonal antibodies (mAbs) offer an alternative that can address all of these limitations oftraditional vaccines. A controlled dose of a mAb(s) of known specificity and known protective activity can be administered, providinginstantaneous immunity to the Warfighter. With the use of well-characterized point mutations to the constant region of a mAb, providing 6-12months of protection should be feasible. The goal of this overall effort is to develop a mAb-based intramuscularly administered vaccinealternative for the Warfighter that would confer immediate immunity for 6-12 months.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government